700255

antibody from Invitrogen Antibodies

Targeting: PTK2 FADK, FAK, FAK1, PPP1R71

Provider product page for 700255

Western blot

ELISA

Antibody data

Antibody Data
Antigen structure
References [42]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [2]
Immunohistochemistry [3]
Flow cytometry [1]
Other assay [24]

Submit

Product number: 700255 - Provider product page
Provider: Invitrogen Antibodies
Product name: Phospho-FAK (Tyr397) Recombinant Rabbit Monoclonal Antibody (31H5L17)
Antibody type: Monoclonal
Antigen: Synthetic peptide
Reactivity: Human, Mouse
Host: Rabbit
Isotype: IgG
Antibody clone number: 31H5L17
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

PTK2 protein structure - 700255 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis of FAK showing staining in the cytoplasm of paraffin-embedded human cervices carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a FAK monoclonal antibody (Product # 700255) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis of FAK showing staining in the cytoplasm and membrane of paraffin-embedded mouse spleen tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a FAK monoclonal antibody (Product # 700255) diluted in 3% BSA-PBS at a dilution of 1:20 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis of Phospho-FAK pTyr397 in formalin-fixed, paraffin-embedded human breast (top left), gastric (top right), and thyroid carcimona (bottom) using a Phospho-FAK pTyr397 monoclonal antibody (Product # 700255) at a dilution of 1:50. Staining was visualized using DAB and images were taken at a magnification of 40x. Results show cytoplasmic staining in tumor cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Nuclear translocation of FAK in ECs. ( A , B ) MS1 cells were stimulated with 30 ng/ml VEGF for indicated times. They were lysed and fractionated to cytoplasmic and nuclear portions, and analyzed by immunoblotting using indicated antibodies. GAPDH was used as a cytoplasmic marker and RARP as a nuclear marker ( A ). The relative levels of FAK are quantified ( B ). n = 3, mean +- SEM. *p < 0.05. N.S., not significant. ( C , D ) MS1 cells were held in suspension for 30 min, and re-plated for 30 or 60 min on dishes coated with 10 mug/ml fibronectin. They were then analyzed as in A ( C ). The relative levels of FAK are quantified ( D ). n = 3, mean +- SEM. *p < 0.05. ( E , F ) MS1 cells were treated with FAK kinase inhibitor PF-271 or vehicle for 12 hours followed by VEGF stimulation for indicated times. They were then analyzed as in C. The relative levels of nuclear FAK are quantified ( F ). n = 3, mean +- SEM. *p < 0.05. Full-length western blots are presented in Supplementary Figures 7 - 9 .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 ATC application activated FAK signaling and induced differentiation of hESCs. ( A ) Adherent colony of hESCs stained with DAPI (blue), E-cadherin (yellow) and pFAK (purple) with and without ATC stimulation (30 min). ( B ) Corrected fluorescence intensity of E-cadherin, pFAK activation and Oct4 after 30 min ATC stimulation compared with control group. Scale bars 50 um. All quantifications were from at least 3 independent experiments with two replicates per experiment. Unpaired t test p values *

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunohistochemical staining of FAK (A, B, E, G) and pFAK (C, D, F, H) proteins in osteosarcoma and normal cancellous bone tissues A. FAK was overexpressed in 61.95% (70/113) of osteosarcoma cells. Tumor cells exhibited cytoplasmic and sometimes membranous immunoreactivity for FAK. B. Low FAK immunohistochemical staining was shown in 43 osteosarcoma patients. C. pFAK was mainly expressed in the cytoplasm of osteosarcoma cells in 37.17% (42/113) of cases. D. Low phospho-FAK immunohistochemical staining pFAK was shown in 71 osteosarcoma patients. E. No FAK immunohistochemical staining was observed in normal cancellous bone tissues. F. No pFAK immunohistochemical staining pFAK was observed in normal cancellous bone tissues. G. FAK immunohistochemical staining was not present in negative controls. H. pFAK immunohistochemical staining was not present in negative controls. Results shown here are representative images, x400 magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 FAK protein expression and FAK phosphorylation in siRNA treated osteosarcoma, control and mock group cells A. Western blot analysis of FAK and pFAK in MG-63 cells from control, mock, F1 siRNA, F2 siRNA and F3 siRNA groups. GAPDH was used as a control for protein load and integrity. B. Western blot analysis of FAK and pFAK in 143B cells from control, mock, F1 siRNA, F2 siRNA and F3 siRNA groups. GAPDH was used as a control for protein load and integrity. C. The bar chart demonstrates the ratio of FAK and pFAK protein to GAPDH by densitometry in MG-63 cells. The data are means +- SEM. D. The bar chart demonstrates the ratio of FAK and pFAK protein to GAPDH by densitometry in 143B cells. The data are means +- SEM.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Hic-5 expression in CAFs indirectly regulates tumor cell growth and signaling. A) Representative sections from end point tumors stained with Ki67. B) Quantification of the percentage of Ki67 and EPCAM positive cells. n=4 mice for each genotype. The slides were blinded prior to analysis. C) Representative sections of end point tumors stained for FAK pY397 and EPCAM. The inset shows reduced FAK pY397 fluorescence intensity in the Hic-5 -/- ;PyMT tumor cells, scale=25mum. D) Quantification of the ratio of mean fluorescence intensity (M.F.I.) of FAK pY397 and EPCAM, n=3 mice for each genotype. E) Representative western blots of whole tumor lysates and subsequent quantification of (F) FAK Y397 and (G) ERK 1/2 phosphorylation. n=3 mice of each genotype (H) Cell proliferation in vitro was assessed using an XTT assay. n=3 independent experiments. The data represent the mean +- S.E.M. * p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 8: Disruption of collagen matrix by BAPN results in loss of integrin signaling in vascular cells. (A) Flow cytometry gating strategy for BSA-488-labeled B. schlosseri vascular cells after formaldehyde fixation and methanol permeabilization. (B) Representative flow cytometry histogram for quantifying phosphorylated Y397 FAK (pY397FAK) in B. schlosseri vascular cells. FAK inhibitor (FAK14) was used a positive control for blocking FAK phosphorylation. (C) Percentage of vascular cells with high FAK phosphorylation for B. schlosseri colonies after indicated treatment for 4 h ( n = 3 per condition). * p < 0.05 as determined by an unpaired Student's t test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 CTEN acts as a binding partner of integrin beta1 and increases the activity of FAK and RhoA. ( a ) Whole cell lysate of RWPE-1 were coimmunoprecipitated (CoIP) with anti-CTEN antibody or normal rabbit IgG. The precipitates were examined by immunoblotting (IB) with anti-integrin beta1 and anti-CTEN antibodies. ( b ) Inducible EGFP-expressing (aON-EGFP) or CTEN-expressing (aON-CTEN) RWPE-1 cells were incubated in 3D culture system for 6 days in the presence of doxycycline (0.2 mug/mL). The cells were collected at the indicated time and the protein levels were examined by Western analyses using the indicated antibodies. alpha-tubulin was used as a loading control. The densities of the protein bands from the Western blot were quantified. The levels of the phosphorylated FAK Y397 (pFAK Y397 ) was normalized to those of the total FAK. The ratio of pFAKY397/FAK in each group was presented. ( c ) RWPE-1 cells were transfected with the indicated siRNA. The GTP-RhoA in RWPE-1 lysates was purified using GTP-RhoA pull-down assays as described in Materials and Methods and examined by Western blot analyses with an anti-RhoA antibody. The protein levels in whole cell lysates were also examined by Western analyses using the indicated antibodies. Total RhoA was used as loading control. The densities of the protein bands from the Western blot were quantified. The levels of Rho-GTP was normalized to those of total RhoA. The ratio of Rho-GTP/total RhoA was presented.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. SHANK2 R240 methylation activated endosomal FAK signals. ( A ) Phosphorylated/total FAK and cortactin were determined in MCF-7 cells expressing the indicated Flag-tagged PRMT7. Western blot was performed with the indicated antibodies. ( B ) Phosphorylated/total FAK and cortactin were determined in MDA-MB-231 cells with or without stable expression of the indicated SHANK2 shRNA or a control shRNA. Western blot was performed with the indicated antibodies. ( C ) Phosphorylated/total FAK and cortactin were determined in MDA-MB-231 cells with or without expressing SHANK2 shRNA and with or without reconstituted expression of WT SHANK2 or SHANK2 R240K mutant. Western blot was performed with the indicated antibodies. ( D ) Phosphorylated/total FAK and cortactin were determined in MDA-MB-231 cells expressing SHANK2 shRNA with or without reconstituted expression of WT SHANK2 or SHANK2 R240K or SHANK2 R240F mutant, SHANK2 R240F were treated with GSK2256098 (10 µM) or DMSO as control. Western blot was performed with the indicated antibodies. ( E ) Phosphorylated/total FAK and cortactin were determined in MCF10A cells co-transfected with SHANK2 and/or FAK plasmids. Western blot was performed with the indicated antibodies. ( F ) Phosphorylated/total FAK and cortactin were determined in MDA-MB-231 cells expressing SHANK2 shRNA with or without reconstituted expression of WT SHANK2, SHANK2 R240K or SHANK2 R240F mutant. SHANK2 R240F group was treated with dynasore (80 uM) or DM

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8. Arginine methylation at SHANK2 R240 promoted metastasis through activates FAK signalling. ( A ) Equal numbers of MDA-MB-231 cells expressing SHANK2 shRNA with or without reconstituted expression of WT SHANK2, SHANK2 R240K or SHANK2 R240F mutant. SHANK2 R240F group was treated with GSK2256098 or DMSO. Cells were tail-vein injected into BALB/c nude mice, and lung metastasis was determined. The gross appearance of the lungs and the tumour nodules on the lungs were examined. Tumours were paraffin embedded and stained with H and E at Day12. n = 5 tumours in each group. IHC analyses of tumour tissues were performed with anti-p-FAK or anti-p-cortactin antibody. Scale bars,100 um. ( B ) The number of visible surface metastatic lesions in lungs was counted. (n = 5 mice for each group, **p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Adhesion of MG-63 cells to different substrates, active focal adhesions and actin cytoskeleton. MG-63 cells were seeded on solid and porous titanium disks, and on poly-L-lysine-coated microscopic glass coverslips, and incubated for 4 days, then processed for indirect immunofluorescence analysis. Actively signaling focal adhesions were visualized using a phospho-specific (pTyr 397 ) anti-focal adhesion kinase (FAK) antibody (red), and the actin cytoskeleton was decorated with Alexa488-conjugated phalloidin (green). Merged images, and images zoomed in on selected areas (boxed) are shown below. Numerous active focal adhesions (red puncta, depicted by arrows) and actin stress fibers (green filaments) were clearly detectable on solid titanium and coverslips, but not on porous titanium consistent with data presented in Figure 3 . Scale bars representative for all images and zoomed in areas are given in mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Adhesion of MG-63 cells to different substrates, vinculin and phospho-FAK co-localization. MG-63 cells were seeded on solid and porous titanium disks, and on poly-L-lysine-coated microscopic glass coverslips, and incubated for 4 days, then processed for indirect immunofluorescence analysis. ( A ) Focal adhesions were visualized using anti-vinculin specific antibodies (red), active focal adhesions were visualized using phospho-specific (pTyr 397 ) anti-FAK antibodies (red), and cell nuclei were stained with DAPI (blue). Merged images, and images zoomed in on selected areas (boxed) are shown below. Numerous typical focal adhesions (yellow/orange puncta, depicted by arrows) double-labeled with both antibodies were clearly detectable on solid titanium and coverslips. Some may also be present in cells on porous titanium. ( B ) Total number of active focal adhesions per cell were determined by counting phospho-FAK positive adhesions (yellow/orange comma) in 18 cells on each substrate. Data are mean +- s.e.m. ; *p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 alpha TAT1 downregulation decreased F-actin and altered alpha -adaptin distribution. ( a ) Confocal images of A549 cells visualized with Alexa Fluor 488 phalloidin (green) and immunostained with anti-vinculin antibody (red). ( b ) Confocal images of metaphase HeLa cells visualized with Alexa Fluor 488 phalloidin. Single optical section of the middle plane is shown. ( c ) pTyr397-PTK2 level determined by western blotting. The same protein extract was used in Figures 1a and 2c , therefore the same blotting of beta -Tu is presented in both figures. ( d ) Confocal images of metaphase HeLa cells immunostained with anti- alpha -adaptin antibody. Single optical section of the bottom or middle planes are shown. The signal intensity across the dashed lines is plotted in the right panel and the cartoon below indicates the relative position of the metaphase cell. Scale bar, 10 mu m.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 | Nuclear and chromatin alterations accompany phenotypic changes induced by ECM stiffness. a , The hypothesis underlying this study is that ECM properties can stabilize normal phenotypes or make phenotypic transitions more permissive through chromatin alterations. b , Immunofluorescence staining for F-actin, vimentin, phosphorylated FAK (Y397), and beta4 integrin in MCF10A acini after 14 days in soft (top) or stiff (bottom) matrices (representative images selected from 15, 3, 5, and 5 images per group respectively). c , Representative outlines of cell clusters from soft (top) and stiff (bottom) matrices. d , Quantification of roundness of cell clusters from at least three independent replicates (median +- 95% C.I.). Significance determined by Mann-Whitney test. e , Quantification of invasive clusters (n >= 5, mean +- S.D.) Significance determined by unpaired t-test. f , Color map of nuclear curvature for cells in soft (top) and stiff (bottom) matrices. Scale bar represents 2 mum and color bar ranges from -20 to 20 mum -1 . g , Distribution of curvature values, showing more regions of extreme curvature for cells in stiff matrices. Distributions were significantly different by Kolmogorov-Smirnov test (p < 0.0001, n >= 11). h , TEM micrographs of nuclei from cells in soft or stiff matrices at 2,000X (left) and 10,000X (right) magnification (representative images from at least 16 images per group). i , Distribution of measured chromatin thickness at each pixel around nucle

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 FAK in human Wilms tumor (WT) samples and patient derived xenografts (PDX). ( A ) H&E staining demonstrating PDX COA 25 ( left lower panel ) recapitulated the predominant epithelial histology of the patient's primary renal WT ( left upper panel ) and PDX COA 42 ( right lower panel ) recapitulated the predominant blastemal histology of the patient's liver metastasis ( right upper panel ). ( B ) Immunohistochemistry staining with antibodies for FAK Y397 and total FAK was performed on the primary renal tumor, liver metastasis, and PDXs - COA 25 and COA 42. Negative controls were included for each sample ( inserts ). Staining for FAK Y397 and total FAK was positive in all samples and located in tumor cell cytoplasm and membrane. ( C ) Immunoblotting for FAK Y397 and total FAK was performed on COA 25 and COA 42 cell lysates. Y397 FAK and total FAK were detected in both PDXs.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 LPA induces formation of actin stress fibers and phosphorylation of MLC and FAK in HTM cells. Serum-starved HTM cells (24 hours) treated with LPA (20 muM for 2 and 6 hours) showed significant increase in the levels of phosphorylated MLC (p-MLC; panel [A]) and FAK (p-FAK; panel [C]) compared with the control cells, based on quantitative immunoblot analyses. Values are mean +- SEM. n = 4, *P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Cell-extracellular matrix signaling is inhibited by GPR56 expression in vivo . (A) GPR56 depletion leads to increased p-FAK staining in 1-week metastases. Top: lung sections from mice injected with MC-1 or 451LuR cells expressing control-shRNA and GPR56-shRNA were sectioned and stained with the anti-p-FAK antibody (green). Red: human-specific anti-human nuclei (huNu) antibody to label human cells. Blue: DAPI, for nuclei. Bottom: quantitation of p-FAK staining intensity. The intensity was measured using the ImageJ software (see Materials and Methods ). (B) GPR56 depletion leads to increased p-FAK staining in 4-week (MC-1) and 3-week (451LuR) metastases. Top: lung sections from mice injected with MC-1 or 451LuR cells expressing control-shRNA and GPR56-shRNA were sectioned and stained with the anti-p-FAK antibody (green). Red: human-specific anti-huNu antibody to label human cells. Blue: DAPI, for nuclei. Bottom: quantitation of p-FAK staining intensity. The intensity was measured using the ImageJ software (see Materials and Methods ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 LIF regulates focal adhesion molecules. a Detection of endogenous focal adhesion kinases in cancer cells via western blot using GAPDH as a loading control. b LIF regulates the spatial distribution of activated focal adhesion kinases. Cells were labeled with antibodies against phospho-PXN (Y118) or phospho-FAK (Y397). Alexa Fluor 488 phalloidin (green) was used to stain F-actin. Blue, nuclear staining. Scale bars, 10 mum. c Live imaging of focal adhesion during transendothelial invasion. Cancer cells expressing LifeAct-RFP were pre-labeled with Talin-GFP and plated onto the HUVEC layer. Images were captured 24 h post-plating. Blue, nuclei labeled with Hoechst33342. Scale bars, 20 mum. The white arrow indicates the damaged area caused by Talin-rich elongated protrusion. d Representative images of LIF, p-PXN (Y118), and p-FAK (Y397) expression in paraffin-embedded consecutive NPC tissue sections. Scale bars, 50 mum. e , f Correlation analyses based on IHC scores (Spearman's correlation test). Correlations were evident between LIF and p-FAK (Y397) ( e ) and LIF and p-PXN (Y118) ( f )